Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors

BACKGROUND: Hepatocellular carcinoma (HCC) remains difficult to treat due to limited effective treatment options. While the proteasome inhibitor bortezomib has shown promising preclinical activity in HCC, clinical trials of bortezomib showed no advantage over the standard-of-care treatment sorafenib...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Jhin Jieh, Hooi, Lissa, Dan, Yock Young, Bonney, Glenn K., Zhou, Lei, Chow, Pierce K.-H., Chee, Cheng Ean, Toh, Tan Boon, Chow, Edward K.-H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377092/
https://www.ncbi.nlm.nih.gov/pubmed/35971164
http://dx.doi.org/10.1186/s13046-022-02436-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377092/
https://www.ncbi.nlm.nih.gov/pubmed/35971164
http://dx.doi.org/10.1186/s13046-022-02436-9

Ejemplares similares